Monitor early TUDRIQEV prescription and reimbursement data over the next 60 days as the launch ramps; confirmatory IGNYTE-3 trial enrollment updates will be critical for sustained valuation. The recent dilutive offering may cap near-term upside, but the approval catalyst is transformative for the stock.
Drug in focus
REPL drug pipeline →TUDRIQEV
● Neutral Named in this press release- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved and commercially available in the U.S. since October 2026.
- Next catalyst
- None dated
What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 14 $14.97entry
- T+1 · 3mo ago −2.27%α −1.80% · $14.63
- T+5 · 3mo ago −1.34%α +0.03% · $14.77
- T+20 · 2mo ago −12.42%α −10.43% · $13.11
- T+60 · 8d ago +48.70%α +51.74% · $22.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Replimune reported a modest EPS beat ($-0.72 vs $-0.77 consensus) for Q1 FY2026, but the headline is the FDA accelerated approval of TUDRIQEV (RP1) for advanced melanoma, announced August 6, 2026. The company is launching within 60 days, recently completed a $150M offering to fund commercialization, and appointed a new CCO. The approval transforms Replimune into a commercial-stage biotech, though the dilutive offering and need for confirmatory trial data temper the outlook.
Key Financial Metrics
Key Facts
- FDA accelerated approval of TUDRIQEV (RP1) + nivolumab for advanced melanoma on August 6, 2026; launch within 60 days
- Q1 FY2026 EPS $-0.72 beat consensus $-0.77 by 6.5%; net loss improved to $69.8M from $86.7M YoY
- Cash, equivalents & short-term investments $195.3M at June 30, 2026; plus $141M net proceeds from August offering extends runway >12 months
- Appointed Michelle DiNapoli as Chief Commercial Officer, effective August 18, 2026
- Completed $150M underwritten public offering on August 10, 2026 (~13% dilution) to support launch and confirmatory trial
Financial Impact
EPS beat of $0.05 (6.5%) vs consensus; net loss narrowed 19.5% YoY; cash burn $73.6M in Q1; $141M net offering proceeds extend runway beyond 12 months
Risk Factors
- Confirmatory trial (IGNYTE-3) overall survival readout not expected until 2030; accelerated approval could be withdrawn if clinical benefit not verified
- Commercial execution risk as a first-time product launcher; competition from existing melanoma therapies
- ~13% dilution from recent offering; potential for additional capital raises if launch costs exceed expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345284 |
Track record
32 reports on REPL
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers